https://www.avient.com/sites/default/files/2023-08/QRG for suppliers on invoicing%5B50%5D.pdf
On the Orders page, you can do one of the following:
o Click the Create Invoice ( ) icon in the Actions column of the Purchase Orders table
o Click on the PO Number link to open the purchase order and click on the Create Invoice
button
4
3.
The selected or newly created legal entity is added to your invoice.
4.
https://www.avient.com/sites/default/files/2023-04/Advanced simulation captures part performance for fibre reinforced thermoplastics_Case_Study.pdf
In Figure 4, the failure location between the isotropic
modelling approach and the Digimat anisotropic modelling
approach is identical.
Figure 1: Tensile test data as a function of the fibre orientation 0°
(orange), 45° (green), 90° (blue)
https://www.hexagonmi.com
Figure 4: Failure location in the flexural test for the isotropic modelling
Figure 6: Failure location in the tensile test for the isotropic modelling
approach (left), Digimat anisotropic modelling approach (middle) and
reality (right)
Figure 3: Flexural test results with the isotropic modelling approach
(orange) and Digimat anisotropic modelling approach (green)
Figure 5: Tensile test results with the isotropic modelling approach
(orange) and Digimat anisotropic modelling approach (green)
Figure 5 shows the tensile test results with, again,
a convincing advantage for the Digimat anisotropic
modelling approach against the isotropic modelling
approach.
https://www.avient.com/sites/default/files/resources/PolyOne%2520Terms%2520and%2520Conditions%2520of%2520sale%2520France.pdf
All limitations and exclusions of Seller's
liability shall also apply to the personal liability of its
salaried and other employees, co-workers and agents
of Seller acting within the performance of their
contractual obligations.
4.
Toute
limitation et exclusion de la responsabilité du Vendeur
s'appliquera également à la responsabilité personnelle
de ses salariés et des autres employés, collaborateurs
et mandataires du Vendeur agissant dans le cadre de
l'exécution de leurs obligations contractuelles.
4.
PRIX ET CONDITIONS D'AJUSTEMENT
Le Vendeur pourra modifier les conditions de prix et
de transport à tout moment précédant l’expédition,
- 4 -
PAI-376900v1
governing or controlling such activity.
https://www.avient.com/sites/default/files/2024-12/Terms and Conditions of Sale for Colombia %28English and Spanish Translation%29.pdf
Upon receipt of a notice of an alleged claim,
Seller may suspend all further deliveries.
4.
Al recibir un aviso de una supuesta
reclamación, el Vendedor puede suspender todas las entregas
posteriores..
4.
https://www.avient.com/sites/default/files/2024-12/Terms and Conditions of Sale for Japan %28English and Japanese Translation%29.pdf
4.
The act of providing a sample or
developmental material does not operate as
permission, recommendation, or inducement to
practice any patented invention without
permission of the patent owner.
4.
買主は、売主が発行する請求書に記
載された支払時期及び支払場所において、本取引条
4
transfer, within the time, and at the location
indicated on Seller’s invoice.
https://www.avient.com/sites/default/files/resources/Investor%2520Day%2520-%2520May%25202012%2520-%2520Operational%2520Excellence.pdf
Kedrowski
Page 38
Operational Excellence
• Operational Excellence is a never-ending quest
for improvement in response to the voice of our
customers and shareholders
• It is all about strengthening our capabilities to
deliver value flawlessly to our customers deliver value flawlessly to our customers
• It challenges us to enhance our
productivity, profitability, and efficiency
in all phases of our business, from
safety to quality to waste elimination
to environmental stewardship
Page 39
Lean Six Sigma Initiative
• In 2009, Lean Six Sigma was launched to
improve execution skills across all
businesses, functions, and global regions
• A company-wide diagnostic was
conducted, resulting in identification of six conducted, resulting in identification of six
strategic improvement platforms
• Financial targets were estimated,
resources identified and trained
results delivered
,
Page 40
PolyOne OSHA Recordable Incidence Rate
4
5
6
5.1
Safety Performance
*Rubber And Plastics Manufacturing Industry (2010 Bureau of Labor Statistics).
0
1
2
3
2005 2006 2007 2008 2009 2010 2011 Industry
Average
1.4 1.3
1.1 1.1 0.85 0.65
0.57
Page 41
• Exemplary on-time delivery
• Best-in-class working capital
% of sales
81%
87%
88%
95%
93%
92%
94%
2005 2006 2007 2008 2009 2010 2011
On-Time Delivery*
Lean Six Sigma Delivering Results
• Approximately $200M in
cash driven by working
capital improvements
16.2%
14.4%
18.9%
11.7%
9.6% 9.6%
2006 2007 2008 2009 2010 2011
WC % of Sales
2005 2006 2007 2008 2009 2010 2011
*As measured to customer request date
Page 42
40.0%
Percent of Associates
Trained in LSS
World’s Best Start-up
Program in 2009*
World’s Best Business Process
Excellence Program in 2012*
Award-Winning Lean Six Sigma Program
*Both awards received from International Quality and Productivity Center
16.5%
40.0%
2009 2011
Page 43
• Globally leverage strategic supplier
management best practices
• Implement world class demand
management processes
Critical Imperatives
• Improve operational reliability and efficiencies
• Optimize global freight management
Drive 50 – 100 basis points of gross margin expansion per year
Page 44
Page 45
https://www.avient.com/sites/default/files/2021-04/registration-of-legal-entity.pdf
4/16/2021 Comprovante de Inscrição e de Situação Cadastral
https://servicos.receita.fazenda.gov.br/servicos/cnpjreva/Cnpjreva_Comprovante.asp 1/2
Comprovante de Inscrição e de Situação Cadastral
Cidadão,
Con�ra os dados de Identi�cação da Pessoa Jurídica e, se houver qualquer divergência, providencie junto à RFB a sua
atualização cadastral.
https://www.avient.com/sites/default/files/resources/Investor%2520Day%2520-%2520May%25202012%2520-%2520Critical%2520Imperatives.pdf
Page 102
Critical Imperatives – Medium to Long Term
• Continue cultural and paradigm shift from
commodity compounder to collaborative formulator
as One PolyOne
• Accelerate innovation and leverage megatrends to
improve our mix of business with higher-margin improve our mix of business with higher-margin
specialty products
• Increase specialty contribution and advance
globalization via acquisitions
• Drive relentless execution and creative innovation as
key competitive differentiators
Page 103
2011
Proforma ColorMatrix
2015 Target
“Where we are” “Where we expect to be”
1) Operating Income %
Specialty 8.9%
PP&S 7.2%
12 – 16%
9 – 12%
Elevating our Expectations and Yours
PP&S 7.2%
Distribution 5.6%
2) Specialty Platform
% of Operating Income
50%
3) ROIC* (after-tax) 10%
4) Adjusted Annual
EPS Growth
3 yr CAGR = 71%
9 – 12%
6 – 7.5%
65 – 75%
15%
Double Digit Expansion
*ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period
Page 104
https://www.avient.com/investor-center/news/polyone-announces-second-quarter-2019-results
Increases full-year adjusted EPS growth expectations to 4-6%
Assuming we continue to capitalize on these efforts and experience no further decline in demand, we expect to deliver adjusted EPS growth of 4-6% for the full year.
Attachment 4
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-for-needle-hubs-bulletin-cn.pdf
主要特性
在三个通过ISO 13485认证的医疗生产线生
产全球统一的配方,提供全球一致性和供应
链保障
变更控制记录不限于CAS编号级别,降低变
更风险
不含动物源性物质和邻苯二甲酸盐
可将颜色与添加剂相结合,以增强产品性能
和防护性能
•
•
•
•
法规支持
经过预测试的原材料:
- 美国药典(USP)23,第87和88章(VI类)
萃取和生物学评价
- ISO 10993,第4、5、10、11和18部分,
萃取和生物学评价
- 美国药典和欧洲药典中针对USP 、
ICH Q3D可萃取金属和EP3.1聚烯烃的测试的
其他监管支持信息
FDA器械主文件
食品接触符合FDA/EU*要求
•
•
•
针头的标称外径
(mm) 颜色说明 RAL 潘通色号 透明产品代码 不透明产品代码
0.4 中灰色 7035 423 C PP7M665125 PP7M665127
0.45 褐色 8017 7588 C PP8M665294 PP8M665296
0.5 橘黄色 2003 173 C PP2M665298 PP2M665300
0.55 中紫色 4005 7676 C PP4M665290 PP4M665292
0.6 深蓝色 5010 288 C PP5M665894 PP5M665896
0.7 黑色 9005 黑色 C PP9M664950 PP9M664952
0.8 深绿色 6001 7483 C PP6M665687 PP6M665689
0.9 黄色 1021 115 C PP1M665211 PP1M665213
1.1 乳白色 1015 7401 C PP0M665290 PP0M665292
1.2 粉色 3015 502 C PE3M665725 PP3M665727
适用医疗保健使用限制—见下文。
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用:
(1) 接触人体组织或体液长达30天或更长时间;
(2)“整形”(整容或重建)手术;
(3) 生殖植入物或任何节育器械;或者
(4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。